Entry Point Capital, LLC I Teos Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 29,850 shares of ITOS stock, worth $207,756. This represents 0.1% of its overall portfolio holdings.
Number of Shares
29,850Holding current value
$207,756% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding ITOS
# of Institutions
150Shares Held
33.4MCall Options Held
454KPut Options Held
2.45M-
Black Rock Inc. New York, NY3.73MShares$26 Million0.0% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$19.1 Million16.91% of portfolio
-
Bvf Inc San Francisco, CA2.33MShares$16.2 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.09MShares$14.6 Million0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY2.07MShares$14.4 Million0.0% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $248M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...